The sustainable future for health and well-being

In response to fast-spreading communicable diseases and a growing gap in access to healthcare, there is a strong desire to develop sustainable solutions that can improve our global health and well-being. We are working in line with the United Nations’ Sustainable Development Goals to contribute to creating a sustainable future for health.

Sustainability agenda

Responsibility by making a difference

Skilled employees

Responsible business

Quality-assured products

Why?

BICO’s sustainability work aims to strengthen the company’s long-term competitiveness and growth. Carrying out this work responsibly is crucial to BICO’s commercial success, profitability and shareholder value.

The point of departure for the company’s sustainability work is the BICO global policy. It permeates how we conduct ourselves and treat each other, both internally and externally. It describes our corporate culture, how we act in a trust-inspiring way, and how we build long-term relations with colleagues and customers, business partners and suppliers. It also has information on the whistleblower function, introduced to ensure compliance with our policy.

How?

We are convinced that our primary contribution to sustainability is the difference our products make. This includes helping to reduce animal testing decreasing human trials, with our bioprinted tissue, ensuring that drug development is more than patient-safe, and doing our part progressively to end illegal organ trading. We can and we want to make a difference by continuously developing our products from both a user and a cost perspective, so that we can be a competitive alternative in cases where our company and our technology can be chosen above tests on animals.

Who?

At BICO, the executive management team is responsible for sustainability work on the basis of the functions and departments that are represented, and overall responsibility for the work lies with the CEO.

Initiatives

patrick-beznoska-4P702ZWSrHI-unsplash

S.T.E.P.

The Sustainable Tissue Engineering Program is a concerted effort by our R&D scientists to adopt the principles of the 3Rs (replacement, reduction and refinement) and embrace more humane strategies that minimize the need for animal research, such as improving the accuracy and relevance of alternative disease models.

Sustainability symbol

We are committed to developing products that help researchers improve health and well-being. Our sustainability symbol, which you will find on many of our products, includes an embedded QR code so users can learn how our products are making an impact in the field.

Refurbished products

As we continue to innovate and provide new solutions to researchers across the world, we want to ensure that we make it easy to responsibly recycle older devices. To that end, we have created the Responsible Return Program, which rewards customers who return their bioprinters for responsible refurbishing or recycling. Refurbished bioprinters are then used to further democratize the field by making technologies more accessible to labs around the world.
CUSTOMER CASE

3d human skin

The future of cosmetic testing

CTIBiotech, an innovative R&D firm based in Lyon, France, is using CELLINK’s BIO X 3D bioprinter to produce in vitro full skin models from human cells. These bioprinted human skin models, which include sebaceous glands, immune cells or melanocytes, are more physiologically relevant. This improved models enable researchers to investigate sebum production, acne, or atopic dermatitis. 

Additionally, with CTIBIOTECH able to produce over one hundered artifical skin constructs (1 cm2 in size) a high-throughput approach for screening of active ingredients in topical products, aesthetic or medical devices for skincare is now possible.
Tissue-engineering breakthroughs like this are propelling the industry forward, reducing its dependance on animals experimentation, whilst driving down development costs and paving the way for safer and more efficacious beauty and dermatological products.

The $40 billion cosmetic industry is increasingly innovating using in vitro technologies as alternatives to animal experimentation for efficacy and safety testing skin-care and beauty products. Thankfully, advances in tissue engineering, such as the ability to bioprint human tissue models in the lab, have unlocked promising long-term-solutions.